Skip to content

Gabriel Braley

4 papers in the library · publishing 2004-2012

Papers

Sort Most recent Most cited

The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.

Psychopharmacology February 2012 Michelle Carbuto, R Andrew Sewell, Ashley Williams et al.

Delta-9-tetrahydrocannabinol (THC) is one of the few cannabinoid receptor ligands that can be used to probe the cannabinoid system in humans. Despite increasing interest in the cannabinoid receptor system, use of intravenous THC as a research tool has been limited by concerns about its abuse liability and psychoactive effects. This study aims to evaluate the safety of all intravenous THC...

Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology September 2008 Deepak Cyril D'Souza, Mohini Ranganathan, Gabriel Braley et al.

Cannabis is one of the most widely used illicit substances and there is growing interest in the association between cannabis use and psychosis. Delta-9-Tetrahydrocannabinol (Delta-9-THC) the principal active ingredient of cannabis has been shown to induce psychotomimetic and amnestic effects in healthy individuals. Whether people who frequently use cannabis are either protected from or are...

Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans.

Psychopharmacology July 2008 Deepak Cyril D'Souza, Gabriel Braley, Rebecca Blaise et al.

Cannabinoids produce a spectrum of effects in humans including euphoria, cognitive impairments, psychotomimetic effects, and perceptual alterations. The extent to which dopaminergic systems contribute to the effects of Delta-9-tetrahydrocannabinol (Delta-9-THC) remains unclear. This study evaluated whether pretreatment with a dopamine receptor antagonist altered the effects of Delta-9-THC in...

The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology August 2004 Deepak Cyril D'Souza, Edward Perry, Lisa Macdougall et al.

Recent advances in the understanding of brain cannabinoid receptor function have renewed interest in the association between cannabinoid compounds and psychosis. In a 3-day, double-blind, randomized, and counterbalanced study, the behavioral, cognitive, and endocrine effects of 0, 2.5, and 5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 22 healthy individuals,...